Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis.

Dai J, Escara-Wilke J, Keller JM, Jung Y, Taichman RS, Pienta KJ, Keller ET.

J Exp Med. 2019 Sep 23. pii: jem.20190158. doi: 10.1084/jem.20190158. [Epub ahead of print]

PMID:
31548301
2.

Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.

Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y, Zhang J.

J Cancer Res Clin Oncol. 2019 Aug;145(8):1999-2012. doi: 10.1007/s00432-019-02950-y. Epub 2019 Jun 6.

3.

Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.

Ahmed AA, Robinson T, Palande M, Escara-Wilke J, Dai J, Keller ET.

J Cell Biochem. 2019 Oct;120(10):16946-16955. doi: 10.1002/jcb.28954. Epub 2019 May 17.

PMID:
31099068
4.

Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.

Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R, Johnson TM, Beer DG, Feng FY, Zhou W, Chinnaiyan AM.

Cell. 2017 Dec 14;171(7):1559-1572.e20. doi: 10.1016/j.cell.2017.11.040.

5.

Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.

Zhang M, Osisami M, Dai J, Keller JM, Escara-Wilke J, Mizokami A, Keller ET.

Mol Cancer Res. 2017 Apr;15(4):457-466. doi: 10.1158/1541-7786.MCR-16-0392. Epub 2017 Jan 13.

6.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

7.

Targeting the MLL complex in castration-resistant prostate cancer.

Malik R, Khan AP, Asangani IA, CieĊ›lik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM.

Nat Med. 2015 Apr;21(4):344-52. doi: 10.1038/nm.3830. Epub 2015 Mar 30.

8.

Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.

Escara-Wilke J, Keller JM, Ignatoski KM, Dai J, Shelley G, Mizokami A, Zhang J, Yeung ML, Yeung KC, Keller ET.

Prostate. 2015 Feb 15;75(3):292-302. doi: 10.1002/pros.22915. Epub 2014 Oct 18.

9.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM.

Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.

10.

Raf kinase inhibitor protein (RKIP) in cancer.

Escara-Wilke J, Yeung K, Keller ET.

Cancer Metastasis Rev. 2012 Dec;31(3-4):615-20. doi: 10.1007/s10555-012-9365-9. Review.

PMID:
22684368
11.

ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines.

Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X, Keller ET.

In Vivo. 2011 Jan-Feb;25(1):69-76.

PMID:
21282737
12.

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M.

Invest New Drugs. 2011 Dec;29(6):1432-40. doi: 10.1007/s10637-010-9420-8. Epub 2010 Mar 25. Erratum in: Invest New Drugs. 2011 Dec;29(6);1517-8. Cooney, Kathleen A [added]; Mathew, Paul [added]; Pienta, Kenneth J [added]; Escara-Wilke, June [added]; Doyle, Gerald [added]; Al-Hawary, Mahmoud [added]; Keller, Evan T [added].

13.

Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.

Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR, Defeo-Jones D, Hwang C, Sanda MG.

Prostate. 2010 Jun 15;70(9):1002-11. doi: 10.1002/pros.21134.

14.

A safety-modified SV40 Tag developed for human cancer immunotherapy.

Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG.

Drug Des Devel Ther. 2009 Feb 6;2:17-24.

15.

Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.

Ignatoski KM, Friedman J, Escara-Wilke J, Zhang X, Daignault S, Dunn RL, Smith DC, Keller ET.

J Interferon Cytokine Res. 2009 Feb;29(2):105-12. doi: 10.1089/jir.2008.0024.

16.

Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.

Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET.

Cancer Res. 2008 Jul 15;68(14):5785-94. doi: 10.1158/0008-5472.CAN-07-6541.

17.

Heat stress-induced heat shock protein 70 expression is dependent on ERK activation in zebrafish (Danio rerio) cells.

Keller JM, Escara-Wilke JF, Keller ET.

Comp Biochem Physiol A Mol Integr Physiol. 2008 Jul;150(3):307-14. doi: 10.1016/j.cbpa.2008.03.021. Epub 2008 Apr 7.

18.

RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.

Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET.

Prostate. 2008 Jun 1;68(8):820-9. doi: 10.1002/pros.20744.

19.

New trends in the treatment of bone metastasis.

Keller ET, Dai J, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS, Keller J.

J Cell Biochem. 2007 Dec 1;102(5):1095-102. Review.

20.

Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression.

Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W.

J Immunol. 2007 Aug 1;179(3):1423-6.

21.
22.

Immunocytochemical localization of the Menkes copper transport protein (ATP7A) to the trans-Golgi network.

Dierick HA, Adam AN, Escara-Wilke JF, Glover TW.

Hum Mol Genet. 1997 Mar;6(3):409-16.

PMID:
9147644
23.

Supplemental Content

Loading ...
Support Center